Sanofi Tumbled Over 17% in Morning Trading After It Expects Business EPS to Be Roughly Flat in 2024
$Sanofi SA$ tumbled over 17% in morning trading.It expects business EPS to be roughly flat in 2024 compared with this year due to increased research-and-development investment and a strong rebound in 2025.Meanwhile, it plans to separate its consumer health division, probably through a spinoff, as the French drugmaker deepens its focus on cutting-edge medicines and vaccines.